Sirona Biochem (TSX-V:SBM) Corp shares surged 77% to $0.15 on Tuesday after the cosmetic ingredient and drug discovery company announced that clinical trial results for its novel anti-aging compound TFC-1326 have exceeded “even high expectations on key criteria.”
Sirona said scientific results included a 37% increase in skin density along with a 25% improvement in skin radiance.
“We believe even more outstanding results are possible through planned modifications in our formulation and knowledge we have gained from this study,” Sirona Biochem (TSX-V:SBM) Chief Scientific Officer Dr Geraldine Deliencourt-Godefroy said in a statement.
The company noted the clinical trial was designed to assess the compound’s efficacy to reverse aging facial skin, including restoring lost volume and reducing fine wrinkles.
It added that the formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredient.
As well, Sirona said both measured and subjective parameters showed continued improvement through the 12-week study, indicating further improvement likely with longer use.
The trial, which was completed by a leading contract research organization in Paris, France, was independently financed by Sirona to ensure that results can be shared with interested partners, without restrictions, with full results expected to be published in a scientific journal, according to the company.
Furthermore, Sirona stated it is currently engaging industry experts to determine the best path forward to commercialize TFC-1326 and further updates will be provided once the strategy is finalized.
Contact Sean at sean@proactiveinvestors.com